|Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer|
MJ Piccart-Gebhart, M Procter, B Leyland-Jones, A Goldhirsch, M Untch, ...
New England Journal of Medicine 353 (16), 1659-1672, 2005
|Lapatinib plus capecitabine for HER2-positive advanced breast cancer|
CE Geyer, J Forster, D Lindquist, S Chan, CG Romieu, T Pienkowski, ...
New England journal of medicine 355 (26), 2733-2743, 2006
|Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis|
P Cortazar, L Zhang, M Untch, K Mehta, JP Costantino, N Wolmark, ...
The Lancet 384 (9938), 164-172, 2014
|The benefits and harms of breast cancer screening: an independent review|
MG Marmot, DG Altman, DA Cameron, JA Dewar, SG Thompson, ...
British journal of cancer 108 (11), 2205-2240, 2013
|2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial|
I Smith, M Procter, RD Gelber, S Guillaume, A Feyereislova, M Dowsett, ...
The lancet 369 (9555), 29-36, 2007
|Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA. 17|
PE Goss, JN Ingle, S Martino, NJ Robert, HB Muss, MJ Piccart, ...
Journal of the National Cancer Institute 97 (17), 1262-1271, 2005
|A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated …|
D Cameron, M Casey, M Press, D Lindquist, T Pienkowski, CG Romieu, ...
Breast cancer research and treatment 112 (3), 533-543, 2008
|2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with …|
MS Aapro, J Bohlius, DA Cameron, L Dal Lago, JP Donnelly, N Kearney, ...
European journal of cancer 47 (1), 8-32, 2011
|Ribociclib as first-line therapy for HR-positive, advanced breast cancer|
GN Hortobagyi, SM Stemmer, HA Burris, YS Yap, GS Sonke, ...
New England Journal of Medicine 375 (18), 1738-1748, 2016
|Identification of molecular apocrine breast tumours by microarray analysis|
P Farmer, H Bonnefoi, V Becette, M Tubiana-Hulin, P Fumoleau, ...
Breast Cancer Research 7 (2), P2. 11, 2005
|Triple-negative breast cancer: disease entity or title of convenience?|
L Carey, E Winer, G Viale, D Cameron, L Gianni
Nature reviews Clinical oncology 7 (12), 683, 2010
|Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial|
L Gianni, U Dafni, RD Gelber, E Azambuja, S Muehlbauer, A Goldhirsch, ...
The lancet oncology 12 (3), 236-244, 2011
|A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer|
P Farmer, H Bonnefoi, P Anderle, D Cameron, P Wirapati, V Becette, ...
Nature medicine 15 (1), 68, 2009
|EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and …|
MS Aapro, DA Cameron, R Pettengell, J Bohlius, J Crawford, M Ellis, ...
European journal of cancer 42 (15), 2433-2453, 2006
|2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial|
A Goldhirsch, RD Gelber, MJ Piccart-Gebhart, E De Azambuja, M Procter, ...
The Lancet 382 (9897), 1021-1028, 2013
|Breast-cancer adjuvant therapy with zoledronic acid|
RE Coleman, H Marshall, D Cameron, D Dodwell, R Burkinshaw, ...
N Engl J Med 365, 1396-1405, 2011
|Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME II): a randomised controlled trial|
IH Kunkler, LJ Williams, WJL Jack, DA Cameron, JM Dixon
The lancet oncology 16 (3), 266-273, 2015
|11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial|
D Cameron, MJ Piccart-Gebhart, RD Gelber, M Procter, A Goldhirsch, ...
The Lancet 389 (10075), 1195-1205, 2017
|Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer|
M Kaufmann, G Von Minckwitz, EP Mamounas, D Cameron, LA Carey, ...
Annals of surgical oncology 19 (5), 1508-1516, 2012
|Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial|
D Cameron, J Brown, R Dent, C Jackisch, J Mackey, X Pivot, GG Steger, ...
The lancet oncology 14 (10), 933-942, 2013